NCT06237062 - Migraine Survey in Gulf Region | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions

Migraine

Interventions

OTHER

erenumab

This is an observational study, there is no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients will be directed through a link to the full survey.

Trial Locations (6)

112412

RECRUITING

Novartis Investigative Site, Abu Dhabi

Unknown

RECRUITING

Novartis Investigative Site, Al Ain Abu Dhabi

RECRUITING

Novartis Investigative Site, Abu Dhabi

RECRUITING

Novartis Investigative Site, Dubai

RECRUITING

Novartis Investigative Site, Ras al-Khaimah

RECRUITING

Novartis Investigative Site, Sharjah city